MedTrace Logo

Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

NCT01363700 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2014-11-19

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to demonstrate safety and efficacy of DE-114 ophthalmic solution compared to its Placebo and Olopatadine hydrochloride 0.1% ophthalmic solution in patients with allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

DE-114 ophthalmic solution

DRUG

Placebo ophthalmic solution

DRUG

Olopatadine Hydrochloride 0.1% Ophthalmic Solution

Sponsors & Collaborators

  • Santen Pharmaceutical Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
20 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2012-06-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01363700 on ClinicalTrials.gov